Insmed (NASDAQ:INSM) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.
Shares of Insmed (INSM) opened at $24.09 on Wednesday. Insmed has a fifty-two week low of $11.49 and a fifty-two week high of $33.94. The company has a current ratio of 15.21, a quick ratio of 15.21 and a debt-to-equity ratio of 0.13. The company has a market cap of $1,850.00, a PE ratio of -7.72 and a beta of 1.09.
INSM has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Wednesday, January 17th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Insmed in a report on Thursday, January 4th. Cowen reissued a “buy” rating and set a $54.00 price objective on shares of Insmed in a report on Friday, November 3rd. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $36.67.
COPYRIGHT VIOLATION NOTICE: “Insmed (INSM) to Release Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/insmed-insm-to-release-quarterly-earnings-on-wednesday.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.